Respana Therapeutics, Inc.

Philadelphia, PA

UEI
QGKNUK6SJUW4
CAGE
7TUT8
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
3675 Market St #200, Philadelphia, PA 19104, USA
Website
respana-therapeutics.com
Founded
2017
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Treatment of inflammatory complications of respiratory infection R42AI162590 National Institute of Allergy and Infectious Diseases (NIH) $5,665,594
Treatment of inflammatory complications of viral pneumonia R41AI162590 National Institute of Allergy and Infectious Diseases (NIH) $511,691
Novel therapeutic monoclonal antibody targeting SP-R210 isoforms to prevent influenza disease progression and… R41AI136294 National Institute of Allergy and Infectious Diseases (NIH) $298,498

Quick answers

Is Respana Therapeutics, Inc. registered in SAM.gov?

Yes. Respana Therapeutics, Inc.'s SAM.gov registration is active through January 6, 2027.

What is Respana Therapeutics, Inc.'s most recent federal award?

Respana Therapeutics, Inc.'s most recent federal grant award is Treatment of inflammatory complications of respiratory infection (R42AI162590), from National Institute of Allergy and Infectious Diseases (NIH), on June 20, 2022.

On GovTribe

See Respana Therapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login